SCID – RAG1/RAG2 Deficiency
A form of Severe Combined Immunodeficiency caused by mutations in the recombination-activating genes RAG1 or RAG2, disrupting normal T and B cell receptor formation and ranging from classic SCID to the inflammatory Omenn syndrome spectrum.
- T-B-NK+ SCID Subtype
- Newborn Screening Detectable
- Curative HSCT Pathway
- Typical Onset
- Birth to Early Infancy
- Inheritance Pattern
- Autosomal Recessive
- Key Genes
- RAG1, RAG2
- Detected By
- Newborn Screening (TREC Assay)
Condition Overview
SCID due to RAG1 or RAG2 deficiency is caused by mutations in the genes encoding the recombination-activating gene proteins, which are essential for V(D)J recombination, the process that generates the diverse repertoire of T and B cell antigen receptors.
Complete loss of RAG1 or RAG2 function results in classic SCID, with absent T and B lymphocytes but preserved natural killer cells. Partial, hypomorphic mutations that retain some residual recombination activity can instead cause Omenn syndrome, a distinct presentation marked by inflammatory skin disease, lymphadenopathy, and an expanded population of dysfunctional, self-reactive T cells, rather than a simple absence of lymphocytes.
Because both presentations are life-threatening if untreated, early recognition, often through newborn screening, and prompt referral to a specialist immunology and transplant center are critical.
Types and Subtypes
RAG1/RAG2-related disease spans a phenotypic spectrum depending on how much residual recombination activity the mutated proteins retain.
Symptoms and Signs
The clinical picture depends on whether the underlying mutations cause classic SCID or the Omenn syndrome phenotype.
Causes and Risk Factors
RAG1/RAG2-related SCID and Omenn syndrome are caused by inherited mutations affecting the recombination-activating gene proteins required for normal lymphocyte receptor gene assembly.
Diagnosis and Investigations
Diagnosis often begins with newborn screening or recognition of the Omenn syndrome clinical picture, followed by immune phenotyping and genetic confirmation.
Disease Severity and Risk Stratification
RAG1/RAG2-related disease does not use a tumor-style staging system. Risk stratification reflects the clinical phenotype, infection status, and timing of diagnosis relative to transplant.
Standard Treatment Options
Treatment focuses on infection prevention and, in Omenn syndrome, control of the inflammatory phenotype, while moving promptly toward curative hematopoietic stem cell transplantation.
Advanced & Emerging Therapies
Transplant remains the cornerstone of curative treatment, with emerging gene therapy research relevant to this SCID subtype as well.
Cellular Therapy
Allogeneic Hematopoietic Stem Cell Transplantation
The established curative approach for both classic RAG-deficient SCID and Omenn syndrome.
Immunotherapy
Pre-Transplant Immunosuppressive Therapy
Used in Omenn syndrome to control autoreactive T cell-driven inflammation before proceeding to transplant.
Gene Therapy
Investigational Autologous Gene Therapy
Gene therapy research is progressing across several SCID subtypes; availability for RAG1/RAG2-deficient SCID specifically should be confirmed with a specialist academic center.
Biomarkers & Precision Medicine
Immune and genetic markers guide diagnosis, distinguish classic SCID from Omenn syndrome, and inform transplant planning.
When a Second Opinion May Be Important
Because RAG1/RAG2-related disease spans a clinical spectrum from classic SCID to Omenn syndrome, specialist input can refine both diagnosis and treatment sequencing.
Clinical Trials & Research
Prognosis & Outcome Factors
Outcomes depend on whether the presentation is classic SCID or Omenn syndrome, how early diagnosis occurs, and whether transplant proceeds before serious infection or progressive inflammatory disease develops.
Supportive Care and Living with RAG1/RAG2-Deficient SCID
Supportive care protects the infant from infection and manages inflammatory complications while definitive treatment is arranged.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families of infants with RAG1/RAG2-deficient SCID or Omenn syndrome obtain urgent specialist immunology report review, coordinate second opinions, and connect with hospitals experienced in SCID transplant, including cross-border care coordination where relevant.
Get a free case reviewFrequently Asked Questions
It is a form of Severe Combined Immunodeficiency caused by mutations in the RAG1 or RAG2 genes, which are required for normal T and B cell receptor formation.
Omenn syndrome is a distinct presentation seen with partial, hypomorphic RAG1 or RAG2 mutations, marked by inflammatory skin disease, lymphadenopathy, and an expanded population of dysfunctional T cells, rather than a simple absence of lymphocytes.
Many cases are detected through newborn screening using the T-cell receptor excision circle (TREC) assay, though Omenn syndrome may also be suspected based on its characteristic clinical picture.
Allogeneic hematopoietic stem cell transplantation can be curative for both classic SCID and Omenn syndrome, particularly when performed early.
The widespread skin inflammation, lymphadenopathy, and enlarged liver or spleen can resemble severe eczema or graft-versus-host disease, which can delay recognition of the underlying immunodeficiency.
Often yes; immunosuppressive therapy may be used to control the inflammatory T cell-driven disease before proceeding to stem cell transplant.
Yes, genetic testing can identify carrier or affected status in siblings, and HLA typing of siblings is important for donor evaluation.
No, live vaccines should be avoided in infants with suspected or confirmed RAG-related SCID until immune function has been restored.
It follows autosomal recessive inheritance, meaning both parents typically carry one copy of a mutated RAG1 or RAG2 gene.
Yes. CancerFax can help coordinate urgent review of your infant's immunology and genetic reports, facilitate second opinions, and connect your family with hospitals experienced in SCID and Omenn syndrome transplantation, including support for cross-border treatment coordination.
Exploring Care Options for SCID – RAG1/RAG2?
Send your medical reports for specialist review and connect with centers experienced in primary immunodeficiency and inherited metabolic-inflammatory disease management.